Lazarus Philip, Zheng Yan, Runkle E Aaron, Muscat Joshua E, Wiener Doris
Department of Pharmacology, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Pharmacogenet Genomics. 2005 Nov;15(11):769-78. doi: 10.1097/01.fpc.0000175596.52443.ef.
The nicotine-derived tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is one of the most potent and abundant procarcinogens found in tobacco and tobacco smoke, and glucuronidation of its major metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), is an important mechanism for NNK detoxification. In cigarette smokers and tobacco chewers, there is a wide variation in the urinary levels of the ratio of NNAL to NNAL glucuronide (NNAL-Gluc). To determine whether genetic variation plays a potential role in this inter-individual variability, NNAL-glucuronidating activities were analysed in a series of human liver microsomal specimens and compared with UGT2B17 deletion genotypes in the same subjects. Assays performed in vitro demonstrated that over-expressed UGT2B17 exhibits high O-glucuronidating activity against NNAL. When stratifying subjects by UGT2B17 genotype, a significant or near-significant decrease in NNAL-O-Gluc formation was observed in liver microsomes from individuals who were either heterozygous [(+/0), P=0.07] or homozygous [(0/0), P=0.016] for the UGT2B17 deletion compared to liver microsomes from individuals with intact UGT2B17 alleles [(+/+)]. There was a significant (P<0.01) association between the level of liver microsomal NNAL-O-glucuronide formation and increasing numbers of the UGT2B17 null alleles in the liver microsomal specimens examined in this study, and a significant decrease in NNAL-O-Gluc formation was observed when comparing liver microsomes from individuals who had at least one UGT2B17 allele deleted [(+/0)+(0/0)] versus microsomes from UGT2B17 (+/+) subjects (P=0.004). When stratifying by the median value of NNAL-O-Gluc formation activity, a significantly (P=0.015) higher number of subjects with liver microsomes having low NNAL-O-Gluc formation activity contained the UGT2B17 null genotype compared to subjects with liver microsomes exhibiting high NNAL-O-Gluc formation activity. When stratifying by UGT2B7/UGT2B17 haplotypes, the association between the level of liver microsomal NNAL-O-glucuronide formation and increasing numbers of the UGT2B17 null allele was at the level of statistical significance for subjects with the UGT2B7 (*1/*2) (P=0.05) or UGT2B7 (*2/*2) (P<0.02) genotypes. These data suggest that the UGT2B17 deletion polymorphism is associated with a reduced rate of NNAL detoxification in vivo and may increase individual susceptibility to tobacco-related cancers.
尼古丁衍生的烟草特异性亚硝胺4-(甲基亚硝基氨基)-1-(3-吡啶基)-1-丁酮(NNK)是烟草和烟草烟雾中发现的最具活性且含量丰富的前致癌物之一,其主要代谢产物4-(甲基亚硝基氨基)-1-(3-吡啶基)-1-丁醇(NNAL)的葡萄糖醛酸化是NNK解毒的重要机制。在吸烟者和嚼烟者中,尿中NNAL与NNAL葡萄糖醛酸苷(NNAL-Gluc)的比值水平存在很大差异。为了确定基因变异是否在这种个体间差异中发挥潜在作用,对一系列人肝微粒体标本中的NNAL葡萄糖醛酸化活性进行了分析,并与同一受试者的UGT2B17缺失基因型进行了比较。体外实验表明,过表达的UGT2B17对NNAL表现出高O-葡萄糖醛酸化活性。根据UGT2B17基因型对受试者进行分层时,与具有完整UGT2B17等位基因[(+/+)]的个体的肝微粒体相比,UGT2B17缺失的杂合子[(+/0),P=0.07]或纯合子[(0/0),P=0.016]个体的肝微粒体中观察到NNAL-O-Gluc形成显著或接近显著降低。在本研究中检测的肝微粒体标本中,肝微粒体NNAL-O-葡萄糖醛酸苷形成水平与UGT2B17无效等位基因数量增加之间存在显著(P<0.01)关联,并且当比较至少有一个UGT2B17等位基因缺失[(+/0)+(0/0)]的个体的肝微粒体与UGT2B17(+/+)受试者的微粒体时,观察到NNAL-O-Gluc形成显著降低(P=0.004)。根据NNAL-O-Gluc形成活性的中值进行分层时,与具有高NNAL-O-Gluc形成活性的肝微粒体的受试者相比,具有低NNAL-O-Gluc形成活性的肝微粒体的受试者中含有UGT2B17无效基因型的人数显著(P=0.015)更多。根据UGT2B7/UGT2B17单倍型进行分层时,对于具有UGT2B7(*1/*2)(P=0.05)或UGT2B7(*2/*2)(P<0.02)基因型的受试者,肝微粒体NNAL-O-葡萄糖醛酸苷形成水平与UGT2B17无效等位基因数量增加之间的关联具有统计学意义。这些数据表明,UGT2B17缺失多态性与体内NNAL解毒率降低有关,可能会增加个体对烟草相关癌症的易感性。